OcuLearning › Retina

Crystalline Retinopathy

CHRONIC — Retina

Symptoms

Often asymptomatic; frequently an incidental finding on dilated exam.

Decreased central vision (if associated with macular edema or atrophy).

Key diagnostic indicator: specific drug exposure or systemic medical history.

Clinical Findings

Hallmark

  • Bright, refractile (sparkling) yellow-white intraretinal or intravascular deposits.

Diagnostic triage

  • Location: Perifoveal, diffuse posterior pole, intravascular, or mid-peripheral?
  • Depth: Inner retina (superficial), outer retina/RPE, or intravascular?
  • Systemic Clues: Drug history (Tamoxifen), renal status (Oxalosis), or IV drug use (Talc)?

Specific drug patterns

  • Tamoxifen: Bilateral perifoveal inner-retinal crystals (doughnut pattern); often associated with Cystoid Macular Edema (CME) and whorl-like corneal verticillata.
  • Talc: Yellow-red intravascular refractile particles at arteriolar bifurcations; causes capillary nonperfusion and potentially disc/peripheral neovascularization.
  • Canthaxanthin (Tanning Pills): Symmetric ring of superficial golden crystals in the inner retina; regresses slowly after cessation.

Inherited & systemic patterns

  • Bietti Crystalline Dystrophy: Yellow-white crystals at all retinal layers and the limbal corneal stroma; progressive RPE/choriocapillaris atrophy.
  • Oxalosis (Primary or Methoxyflurane): Calcium-oxalate crystals at the RPE level; associated with systemic oxalosis and renal failure.
  • MacTel 2: Tiny glistening crystals on the temporal parafoveal ILM; associated with right-angle venules and foveal thinning.
  • Sjögren-Larsson Syndrome: Foveal crystals associated with ichthyosis and spasticity.
  • Others: Nitrofurantoin, ethylene glycol, and chronic long-standing retinal detachment (cholesterol/oxalate crystals).

Imaging characteristics

  • OCT: Localizes crystals by depth (Inner retina: Tamoxifen/MacTel 2; RPE: Oxalosis/Bietti).
  • IVFA: Identifies capillary nonperfusion (Talc) or macular edema (Tamoxifen).
  • FAF: Highly sensitive for detecting RPE atrophy in Bietti dystrophy.

Etiology

Drug toxicity

  • Tamoxifen: Most common drug cause; risk increases with doses >20 mg/day or cumulative doses >7.7 g.
  • Talc: IV drug abuse involving crushed oral tablets; talc filler lodges at vessel bifurcations.
  • Methoxyflurane: Inhalational anesthetic metabolized to oxalic acid, causing retinal and systemic deposits.
  • Canthaxanthin: Oral tanning agent requiring high cumulative doses (~19 g).

Genetic & metabolic

  • Bietti Dystrophy: Autosomal recessive CYP4V2 mutation affecting lipid metabolism; more common in East Asians.
  • Primary Hyperoxaluria: Inherited oxalate overproduction leading to renal, cardiac, and retinal oxalosis.

Other etiologies

  • MacTel 2: Neurodegenerative condition frequently unmasking occult insulin resistance.
  • West African Crystalline Maculopathy: Benign, stable yellow-white maculopathy in young patients.
  • Ocular Siderosis: Retained intraocular metallic foreign body causing crystalline-like deposits.

Red Flags

Bilateral progressive nyctalopia without drug history → suspect Bietti Crystalline Dystrophy; perform CYP4V2 testing.

Tamoxifen use with new visual symptoms → urgent evaluation for Cystoid Macular Edema (CME).

Retinal crystals in the setting of renal failure → suspect systemic oxalosis; requires urgent nephrology referral.

Talc particles with neovascularization → high risk of vitreous hemorrhage; warrants PRP/Anti-VEGF.

Crystals following trauma → rule out a retained intraocular metallic foreign body.

Investigations

Clinical assessment

  • Slit-lamp biomicroscopy to determine crystal depth, location, and morphology.
  • Corneal exam: Look for limbal crystals (Bietti) and whorl keratopathy (Tamoxifen).
  • Skin exam: Check for IV drug track marks (Talc).

Diagnostics & imaging

  • OCT: Mandatory to detect CME and determine deposit depth.
  • IVFA: Assess for capillary nonperfusion distal to emboli and confirm CME.

Systemic & genetic

  • Renal workup: 24-hour urine oxalate and creatinine if oxalosis is suspected.
  • Lab tests: HbA1c (MacTel 2) and fasting lipids.
  • Genetic testing: CYP4V2 for Bietti dystrophy confirmation.

Treatment

Agent removal

  • Coordinate drug cessation (Tamoxifen, Canthaxanthin, Nitrofurantoin) with the prescribing physician.
  • Tamoxifen: An aromatase inhibitor may be a suitable alternative for postmenopausal patients.

Complication management

  • CME: Topical CAIs or intravitreal steroids.
  • Neovascularization (Talc): Panretinal photocoagulation (PRP) and Anti-VEGF injections.

Systemic support

  • Oxalosis: Urgent nephrology referral for primary hyperoxaluria management.
  • Talc: Addiction-medicine/social-work referral.
  • Progressive Dystrophies: Low-vision rehabilitation.

Clinical Pearl

Tamoxifen, canthaxanthin, and methoxyflurane all deposit intraretinal crystals—always perform a thorough drug history before pursuing expensive genetic or metabolic workups.

Differential Diagnosis

  • Hard exudates (yellow, waxy, non-refractile; associated with edema)
  • Calcific drusen (subretinal; non-vascular location)
  • Retinal arterial emboli (e.g., Hollenhorst plaques)

Related Retina Conditions